RS67713B1 - Kx2‑391/kx‑01 za upotrebu u lečenju aktinične keratoze - Google Patents

Kx2‑391/kx‑01 za upotrebu u lečenju aktinične keratoze

Info

Publication number
RS67713B1
RS67713B1 RS20260134A RSP20260134A RS67713B1 RS 67713 B1 RS67713 B1 RS 67713B1 RS 20260134 A RS20260134 A RS 20260134A RS P20260134 A RSP20260134 A RS P20260134A RS 67713 B1 RS67713 B1 RS 67713B1
Authority
RS
Serbia
Prior art keywords
days
subject
day
compound
administered
Prior art date
Application number
RS20260134A
Other languages
English (en)
Serbian (sr)
Inventor
Min-Fun Rudolf Kwan
Johnson Yiu-Nam Lau
E Douglas Kramer
David Lawrence Cutler
Jane Fang
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS67713(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Publication of RS67713B1 publication Critical patent/RS67713B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
RS20260134A 2017-03-10 2018-03-12 Kx2‑391/kx‑01 za upotrebu u lečenju aktinične keratoze RS67713B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis
EP18764980.1A EP3592355B1 (en) 2017-03-10 2018-03-12 Kx2-391/kx-01 for use in the treatment of actinic keratosis

Publications (1)

Publication Number Publication Date
RS67713B1 true RS67713B1 (sr) 2026-02-27

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260134A RS67713B1 (sr) 2017-03-10 2018-03-12 Kx2‑391/kx‑01 za upotrebu u lečenju aktinične keratoze

Country Status (22)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
US11752156B2 (en) * 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
US20220305021A1 (en) * 2019-06-05 2022-09-29 Athenex, Inc. Methods of treating and/or preventing psoriasis
CA3205857A1 (en) * 2021-01-21 2022-07-28 Michael MOLYNEAUX Compositions and methods for treatment of skin cancers
CN120152984A (zh) * 2023-10-13 2025-06-13 恩康药业科技(广州)有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
US7538252B2 (en) 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
EP2155681B1 (en) 2007-05-17 2018-05-02 Athenex, Inc. Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
WO2010080345A1 (en) * 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
AU2018231144A1 (en) 2019-10-03
US10617693B2 (en) 2020-04-14
MX387658B (es) 2025-03-18
LT3592355T (lt) 2026-02-25
US20230172942A1 (en) 2023-06-08
ES3060528T3 (en) 2026-03-26
JP2020510042A (ja) 2020-04-02
NZ757105A (en) 2026-02-27
RU2019131757A (ru) 2021-04-12
JP2023015269A (ja) 2023-01-31
AU2018231144B2 (en) 2023-12-21
TW201842913A (zh) 2018-12-16
IL269182B1 (en) 2023-07-01
WO2018165647A1 (en) 2018-09-13
JP7502863B2 (ja) 2024-06-19
FI3592355T3 (fi) 2026-02-13
PT3592355T (pt) 2026-02-03
EP4659740A2 (en) 2025-12-10
EP3592355A4 (en) 2021-01-06
CA3055938A1 (en) 2018-09-13
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
AU2024201828B2 (en) 2026-02-19
EP3592355A1 (en) 2020-01-15
TWI841523B (zh) 2024-05-11
PL3592355T3 (pl) 2026-04-07
KR20240090837A (ko) 2024-06-21
AU2024201828A1 (en) 2024-05-02
DK3592355T3 (da) 2026-02-16
EP3592355B1 (en) 2025-12-10
HRP20260155T1 (hr) 2026-03-27
MX2019010707A (es) 2020-01-15
KR20190141661A (ko) 2019-12-24
IL269182B2 (en) 2023-11-01
RU2019131757A3 (https=) 2021-05-31
BR112019018687A2 (pt) 2020-04-07
US20180256589A1 (en) 2018-09-13
US11497750B2 (en) 2022-11-15
ZA202100106B (en) 2022-08-31
JP2025029010A (ja) 2025-03-05
EP4659740A3 (en) 2026-02-18
IL269182A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
RS67713B1 (sr) Kx2‑391/kx‑01 za upotrebu u lečenju aktinične keratoze
Sharma et al. Rosacea management: a comprehensive review
JP2021520373A (ja) Cgrpを阻害する際に使用するための神経毒素
HK1223841A1 (zh) 使用伊维菌素治疗丘疹脓疱性红斑痤疮
KR20140012651A (ko) 파라벤 조성물
RU2741577C2 (ru) Сублингвальное или буккальное введение dim для лечения заболеваний кожи
EP3060304A1 (en) A method for topically treating actinic keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
HK40020549B (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
HK40020549A (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
TW202112379A (zh) 治療及/或預防乾癬之方法
Borelli et al. Topical and Systemic Therapy of Rosacea
Neelima et al. Comprehensive Evaluation of Intradermal Versus Oral Tranexamic Acid in The Treatment of Melasma.
BR122025000862A2 (pt) Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
Gao et al. LB1581 Sex differences in adverse event reporting during treatment with TNF-alpha inhibitors for psoriasis
Kadoya et al. LB1582 Assessment of a newly developed environmental aggressor protection serum (LV-D)
Tadros et al. LB1577 STAR particles for enhanced topical delivery to skin
Ginglinger et al. LB1580 TEM1657 is a new small molecule for the topical and oral treatment of psoriasis
Meier et al. LB1579 Phosphodiesterase-4 inhibition alleviates psoriatic skin phenotype in a psoriasis mouse model
Dermotoi Therapeutics 45